Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach.
暂无分享,去创建一个
Julian Gold | Emiko Masaki | M. Over | J. Gold | B. Stilwell | Wiwat Peerapatanapokin | B Stilwell | C Allers | T OHearn | M Kagone | Mead Over | L Keough | Katherine Marshall | Ana Revenga | Emiko Masaki | Vitillo Rj | W. Peerapatanapokin | Ana Revenga | Katherine Marshall | C. Allers | L. Keough | T. OHearn | M. Kagone | Vitillo Rj
[1] J. Ena,et al. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients , 2003, International journal of STD & AIDS.
[2] B. Masquelier,et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. , 2007, International journal of epidemiology.
[3] Terri Wrin,et al. The prevalence of antiretroviral drug resistance in the United States , 2004, AIDS.
[4] D. Gibb,et al. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial , 2003, The Pediatric infectious disease journal.
[5] B. Clotet,et al. HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] Nigel Rollins,et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis , 2004, The Lancet.
[7] L. Moulton,et al. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials , 2008, The Lancet.
[8] Julio S. G. Montaner,et al. CD4+ T-Cell Count Monitoring Does Not Accurately Identify HIV-Infected Adults With Virologic Failure Receiving Antiretroviral Therapy , 2008, Journal of acquired immune deficiency syndromes.
[9] R. Yolken,et al. Resting energy expenditure and body composition in children with HIV infection. , 1998, Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology.
[10] S. Mora,et al. A 12-Month Treatment With Tenofovir Does Not Impair Bone Mineral Accrual in HIV-Infected Children , 2005, Journal of acquired immune deficiency syndromes.
[11] A. Balasubramanyam,et al. Dysregulated energy expenditure in HIV-infected patients: a mechanistic review. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] H. Zar,et al. Detection of tuberculosis in HIV-infected children using an enzyme-linked immunospot assay , 2009, AIDS.
[13] W. Moss,et al. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. , 2008, The Lancet. Infectious diseases.
[14] Joel E Gallant,et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. , 2006, The New England journal of medicine.
[15] D. Bennett,et al. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance , 2008, Antiviral therapy.
[16] Nontobeko Mpontshane,et al. Zinc or Multiple Micronutrient Supplementation to Reduce Diarrhea and Respiratory Disease in South African Children: A Randomized Controlled Trial , 2007, PloS one.
[17] Mikko Niemi,et al. Pharmacokinetic Interactions with Rifampicin , 2003, Clinical pharmacokinetics.
[18] N. Shaffer,et al. Early Diagnosis of HIV‐1‐Infected Infants in Thailand Using RNA and DNA PCR Assays Sensitive to Non‐B Subtypes , 2000, Journal of acquired immune deficiency syndromes.
[19] P. Reiss,et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. , 2008, The Lancet. Infectious diseases.
[20] J. van den Broeck,et al. The effect of nutritional support on weight gain of HIV‐infected children with prolonged diarrhoea , 2007, Acta paediatrica.
[21] S. Hayashi,et al. Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. , 2003, Pediatrics.
[22] R. de Groot,et al. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. , 2002, Pediatrics.
[23] P. Mcdermott,et al. Disease progression in children with vertically-acquired HIV infection in sub-Saharan Africa: reviewing the need for HIV treatment. , 2007, Current HIV research.
[24] B. Eley,et al. Disseminated bacille Calmette-Guérin disease in HIV-infected South African infants. , 2009, Bulletin of the World Health Organization.
[25] M. Hughes,et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. , 2001, The New England journal of medicine.
[26] D. Haas. Pharmacogenomics and HIV therapeutics. , 2005, The Journal of infectious diseases.
[27] Alimuddin Zumla,et al. Impact of HIV infection on tuberculosis , 2000, Postgraduate medical journal.
[28] D. Katzenstein,et al. Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. , 2005, The Journal of infectious diseases.
[29] V. Arendt,et al. Validation of 2006 WHO Prediction Scores for True HIV Infection in Children Less than 18 Months with a Positive Serological HIV Test , 2009, PloS one.
[30] M. Sharland,et al. PENTA guidelines for the use of antiretroviral therapy, 2004 , 2004, HIV medicine.
[31] J. Giesecke,et al. Risk factors for human immunodeficiency virus infection in Ethiopian children with tuberculosis , 2001, The Pediatric Infectious Disease Journal.
[32] L. Aurpibul,et al. Haematological changes after switching from stavudine to zidovudine in HIV‐infected children receiving highly active antiretroviral therapy , 2008, HIV medicine.
[33] L. Bahamondes,et al. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. , 2008, Fertility and sterility.
[34] J. Arribas. The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens. , 2004, The Journal of antimicrobial chemotherapy.
[35] J. Simoni,et al. Adherence to Antiretroviral Therapy for Pediatric HIV Infection: A Qualitative Systematic Review With Recommendations for Research and Clinical Management , 2007, Pediatrics.
[36] C. Fletcher,et al. Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] W. Tsai,et al. The effects of vitamin A supplementation on the morbidity of children born to HIV-infected women. , 1995, American journal of public health.
[38] W. Fawzi,et al. Vitamin A supplements and diarrheal and respiratory tract infections among children in Dar es Salaam, Tanzania. , 2000, The Journal of pediatrics.
[39] M. Battegay,et al. Immune reconstitution in HIV-infected patients. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[40] J. Wang,et al. Growth velocity, fat-free mass and energy intake are inversely related to viral load in HIV-infected children. , 2000, The Journal of nutrition.
[41] B. Chi,et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. , 2007, JAMA.
[42] G. Maartens,et al. Effect of Rifampicin on Efavirenz Pharmacokinetics in HIV-Infected Children With Tuberculosis , 2009, Journal of acquired immune deficiency syndromes.
[43] G. Maartens,et al. Effect of Rifampicin on Lopinavir Pharmacokinetics in HIV-Infected Children With Tuberculosis , 2008, Journal of acquired immune deficiency syndromes.
[44] B. Eley,et al. Tuberculosis during early antiretroviral-induced immune reconstitution in HIV-infected children. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[45] J. Sleasman,et al. Varicella zoster as a manifestation of immune restoration disease in HIV-infected children. , 2004, The Journal of allergy and clinical immunology.
[46] S. Hammer,et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. , 2001, JAMA.
[47] M. Batterham. Investigating heterogeneity in studies of resting energy expenditure in persons with HIV/AIDS: a meta-analysis. , 2005, The American journal of clinical nutrition.
[48] G. Gray,et al. Efficacy of Short-Course AZT Plus 3TC to Reduce Nevirapine Resistance in the Prevention of Mother-to-Child HIV Transmission: A Randomized Clinical Trial , 2009, PLoS medicine.
[49] James Bethel,et al. Performance Characteristics of HIV-1 Culture and HIV-1 DNA and RNA Amplification Assays for Early Diagnosis of Perinatal HIV-1 Infection , 2003, Journal of acquired immune deficiency syndromes.
[50] T. Puthanakit,et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[51] R. Bollinger,et al. Nevirapine Resistance and Breast-Milk HIV Transmission: Effects of Single and Extended-Dose Nevirapine Prophylaxis in Subtype C HIV-Infected Infants , 2009, PloS one.
[52] S. Khoo,et al. Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro , 1997, Antimicrobial agents and chemotherapy.
[53] O. Kirk,et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration , 2008, The Lancet.
[54] L. Scott,et al. Emtricitabine , 2012, Drugs.
[55] C. Fletcher,et al. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. , 1998, The Journal of pediatrics.
[56] S. Lagakos,et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. , 2007, The New England journal of medicine.
[57] T. Quinn,et al. Survival from 9 months of age among HIV-infected and uninfected Zambian children prior to the availability of antiretroviral therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[58] Robert L. Johnson,et al. Retention, adherence, and compliance: special needs of HIV-infected adolescent girls and young women. , 2003, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.
[59] P. Keiser,et al. Comparison of Nevirapine- and Efavirenz-Containing Antiretroviral Regimens in Antiretroviral-Naïve Patients: A Cohort Study , 2002, HIV clinical trials.
[60] P. Keiser,et al. Comparison of Efficacy of Efavirenz and Nevirapine: Lessons Learned for Cohort Analysis in Light of the 2NN Study , 2003, HIV Clinical Trials.
[61] J. Coffin,et al. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.
[62] I. Hambleton,et al. Tuberculosis and HIV co-infections in Jamaican children. , 2004, West Indian medical journal.
[63] M. Chhagan,et al. Case management of HIV-infected severely malnourished children: challenges in the area of highest prevalence , 2008, The Lancet.
[64] J. Church,et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. , 1995, Pediatrics.
[65] J. Rossert,et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[66] G. Montepiedra,et al. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response. , 2005, The Journal of infectious diseases.
[67] C. Chintu,et al. Tuberculosis in children with human immunodeficiency virus infection. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[68] G. Beall,et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. , 2002, The New England journal of medicine.
[69] P. Graaff,et al. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens , 2007, AIDS.
[70] Paige L. Williams,et al. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. , 2008, The Journal of infectious diseases.
[71] D. Blaauw,et al. Diagnosis of paediatric HIV infection in a primary health care setting with a clinical algorithm. , 2003, Bulletin of the World Health Organization.
[72] H. Kirchner,et al. High level of discordant IGRA results in HIV-infected adults and children. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[73] E. Carter,et al. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[74] S. Steinberg,et al. Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy for Pediatric HIV Infection , 2005, Pediatrics.
[75] R. Gie,et al. A Refined Symptom-Based Approach to Diagnose Pulmonary Tuberculosis in Children , 2006, Pediatrics.
[76] E. Abrams,et al. The reliability of reports of medical adherence from children with HIV and their adult caregivers. , 2003, Journal of pediatric psychology.
[77] Stephanie A. Jones,et al. Can clinical algorithms deliver an accurate diagnosis of HIV infection in infancy? , 2005, Bulletin of the World Health Organization.
[78] C. Rouzioux,et al. HIV-1 RNA detection in plasma for the diagnosis of infection in neonates. The French Pediatric HIV Infection Study Group. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[79] N. Sewankambo,et al. Mortality in HIV-Infected and Uninfected Children of HIV-Infected and Uninfected Mothers in Rural Uganda , 2006, Journal of acquired immune deficiency syndromes.
[80] D. Hoover,et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns , 2005, AIDS.
[81] O. Ramilo,et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children , 2003, The Pediatric infectious disease journal.
[82] S. Zeichner,et al. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. , 2008, The Journal of pediatrics.
[83] J. Park,et al. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. , 2008, Contraception.
[84] A. Baleta. Trial finds simultaneous HIV/tuberculosis treatment beneficial. , 2008, The Lancet. Infectious diseases.
[85] G. Moyle. NNRTI choice: has 2NN changed our practice? , 2003, The AIDS reader.
[86] V. Soriano,et al. Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or Nevirapine , 2003, HIV clinical trials.
[87] Christopher D Pilcher,et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. , 2004, The New England journal of medicine.
[88] J. Church. Immune Reconstitution Syndrome After Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Thai Children , 2007, Pediatrics.
[89] P. Rheenen. The use of the paediatric tuberculosis score chart in an HIV-endemic area. , 2002 .
[90] J. Sterne,et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.
[91] S. Cohn,et al. Issues Regarding Use of Hormonal Contraceptives in Clinical Trials of Antiretroviral Therapy , 2005, Journal of acquired immune deficiency syndromes.
[92] F. Matovu,et al. Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission. , 2008, The Journal of infectious diseases.
[93] D. Faulds,et al. Nelfinavir. A review of its therapeutic efficacy in HIV infection. , 1998, Drugs.
[94] W. Nyandiko,et al. A Systematic Review of Pediatric Adherence to Antiretroviral Therapy in Low- and Middle-Income Countries , 2008, The Pediatric infectious disease journal.
[95] Alimuddin Zumla,et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial , 2004, The Lancet.
[96] C. Dreezen,et al. The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiviral treatment , 2004, International journal of STD & AIDS.
[97] T. Wrin,et al. Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance. , 2005, AIDS research and human retroviruses.
[98] O. Ramilo,et al. Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy. , 2002, The Journal of pediatrics.
[99] Rebecca Hoh,et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. , 2005, The Journal of infectious diseases.
[100] S. Shelburne,et al. Immune reconstitution inflammatory syndrome: more answers, more questions. , 2006, The Journal of antimicrobial chemotherapy.
[101] D. Dunn. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis , 2003, The Lancet.
[102] A. Tomkins,et al. Nutritional recovery in HIV-infected and HIV-uninfected children with severe acute malnutrition , 2008, Archives of Disease in Childhood.
[103] E. Abrams,et al. Care and Treatment of HIV-Infected Children in Africa: Issues and Challenges at the District Hospital Level , 2007, The Pediatric infectious disease journal.
[104] R. Bunnell,et al. Disclosure of HIV Status and Adherence to Daily Drug Regimens Among HIV-infected Children in Uganda , 2006, AIDS and Behavior.
[105] E. Nicastri,et al. Clinical outcome after 4 years follow‐up of HIV‐seropositive subjects with incomplete virologic or immunologic response to HAART , 2005, Journal of medical virology.
[106] Ajit Lalvani,et al. Diagnosis of tuberculosis in South African children with a T cell-based assay: a prospective cohort study , 2004, The Lancet.
[107] G. Aldrovandi,et al. Antiretroviral Pharmacokinetics in the Paediatric Population , 2002, Clinical pharmacokinetics.
[108] D. Boulware,et al. Pediatric HIV immune reconstitution inflammatory syndrome , 2008, Current opinion in HIV and AIDS.
[109] Steven C Johnson,et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[110] Bruno Ledergerber,et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes , 2004, The Lancet.
[111] R. Chandra,et al. Nutrition and immunity: an overview. , 1994, The Journal of nutrition.
[112] J. Volmink,et al. Treatment of latent tuberculosis infection in HIV infected persons. , 2004, The Cochrane database of systematic reviews.
[113] M. Sharland,et al. Triple Nucleoside Reverse Transcriptase Inhibitor Therapy in Children , 2004, Paediatric drugs.
[114] H. Zar,et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial , 2006, BMJ : British Medical Journal.
[115] P. Jeena,et al. Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa. , 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[116] C. Pannuti,et al. Analysis of HIV- type 1 protease and reverse transcriptase in Brazilian children failing highly active antiretroviral therapy (HAART). , 2005, Revista do Instituto de Medicina Tropical de Sao Paulo.
[117] Paige L. Williams,et al. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[118] Akihiko Saitoh,et al. Clinical Outcomes After an Unstructured Treatment Interruption in Children and Adolescents With Perinatally Acquired HIV Infection , 2008, Pediatrics.
[119] Alimuddin Zumla,et al. Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial , 2008, BMJ : British Medical Journal.
[120] I. Williams,et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[121] D. Droz,et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[122] J. van den Broeck,et al. Effect of micronutrient supplementation on diarrhoeal disease among stunted children in rural South Africa , 2008, European Journal of Clinical Nutrition.
[123] T. Self,et al. Rifampin and rifabutin drug interactions: an update. , 2002, Archives of internal medicine.